Opendata, web and dolomites


A Unique Herbal Product for the Symptomatic Treatment of Over Active Bladder

Total Cost €


EC-Contrib. €






Project "SAGAPROPLUS" data sheet

The following table provides information about the project.


Organization address
address: KROKHALSI 5D
postcode: 110
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Iceland [IS]
 Project website
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.2.4. (Sustainable and competitive bio-based industries and supporting the development of a European bioeconomy)
2. H2020-EU.3.2.1. (Sustainable agriculture and forestry)
3. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
4. H2020-EU.3.2.2. (Sustainable and competitive agri-food sector for a safe and healthy diet)
 Code Call H2020-SMEINST-1-2016-2017
 Funding Scheme SME-1
 Starting year 2017
 Duration (year-month-day) from 2017-08-01   to  2017-11-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 


 Project objective

Overactive bladder (OAB) is an emerging condition that significantly impacts the quality of life and daily routine of millions of people. It is characterized by urinary urgency, increased urinary frequency and nocturia. OAB is extremely frequent, affecting more than 500 million people worldwide and its prevalence is expected to increase by 9,2% by 2018. Despite being a widely spread affection, currently there is no effective treatment in the market, and the ones available are associated to adverse reactions and drug-to-drug interactions, leading to up to 88,6% of dropout cases. As a consequence, the market trend is shifting from prescription drugs to products from natural origin. In the recent years, there has been a strong increase in the market for herbal medicinal products in Europe which is looking forward to bio-based solutions. These facts open up a clear opportunity for alternative solutions like the ones developed by SagaMedica, an Icelandic company with 17 years of experience in the field of natural product manufacturing. At SagaMedica we have developed SagaPro, the first new natural product for improving OAB symptoms in decades. It is made from an extract of the leaves of Angelica archangelica, whose activity on the bladder was discovered by SagaMedica’s research team. We have developed a harvesting, extraction and manufacturing process system that has been kept sustainable and eco-friendly. SagaPro provides several advantages compared to current alternatives: 1) Highly effective product, as it has been reported by clinical trials; 2) It has no adverse effects nor drug-to-drug interactions; and 3) It is based in a natural product from a sustainable production and harvesting system, contributing to Europe´s bio-based economy. All these reasons brought high interest of various companies, with cooperation discussions already progressing with three strong players. Several Support Letters prove this market demand.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SAGAPROPLUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SAGAPROPLUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.2.4.;H2020-EU.3.2.1.;H2020-EU.2.3.1.;H2020-EU.3.2.2.)

Stoock (2018)

An Innovative Integrated Field Sensor system providing a precise farming tool to reduce productioncosts and water wastage.

Read More  

TEST4ALL (2018)


Read More  

FucoPol (2017)

An innovative bio-based platform for the cost-competitive production of L-fucose, a building block for Human Milk Oligosaccharides (HMOs).

Read More